Abstract
As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirmed that LDL-C represents the primary or even the only target of treatment. Yet, increasing evidence suggests moving away from a LDL-C target-based approach to a more tailored treatment approach. For example, non- HDL-C has been introduced in the last few years as a target of treatment.
Keywords: Combined dyslipidemia, cholesterol, low-density lipoprotein-cholesterol, small, dense low-density lipoprotein, high-density lipoprotein- cholesterol, non-high-density lipoprotein-cholesterol.
Current Pharmaceutical Design
Title:Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Volume: 19 Issue: 21
Author(s): Manfredi Rizzo, Marcin Barylski, Ali A. Rizvi, Giuseppe Montalto, Dimitri P. Mikhailidis and Maciej Banach
Affiliation:
Keywords: Combined dyslipidemia, cholesterol, low-density lipoprotein-cholesterol, small, dense low-density lipoprotein, high-density lipoprotein- cholesterol, non-high-density lipoprotein-cholesterol.
Abstract: As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirmed that LDL-C represents the primary or even the only target of treatment. Yet, increasing evidence suggests moving away from a LDL-C target-based approach to a more tailored treatment approach. For example, non- HDL-C has been introduced in the last few years as a target of treatment.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, Barylski Marcin, Rizvi Ali A., Montalto Giuseppe, P. Mikhailidis Dimitri and Banach Maciej, Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/13816128113199990324
DOI https://dx.doi.org/10.2174/13816128113199990324 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Lowering Drugs and Gallstones: A Therapeutic Option?
Current Pharmaceutical Design Ligand Based Validated Comparative Chemometric Modeling and Pharmacophore Mapping of Aurone Derivatives as Antimalarial Agents
Current Computer-Aided Drug Design Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Current Vascular Pharmacology Statins: Are They All the Same?
Current Drug Therapy Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Perinatal Management of Fetal Tumors
Current Pediatric Reviews Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology State of the Heart: CMR in Coronary Artery Disease
Current Medical Imaging Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Metabolic Syndrome During Menopause
Current Vascular Pharmacology